FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380355199> ?p ?o ?g. }

• W4380355199 abstract "Abstract Introduction Severe acute respiratory syndrome coronavirus 2 is constantly evolving. The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating variants remains unclear. We sought to describe the real-world use of, and clinical outcomes associated with, early COVID-19 treatments among non-hospitalised patients with COVID-19 at highest risk of developing severe disease in Scotland. Methods Retrospective cohort study of non-hospitalised patients diagnosed with COVID-19 from 1 December 2021 to 25 October 2022, using administrative health data managed by Public Health Scotland and National Records of Scotland. Patients included in the study were aged ≥18 years, met at least one of the National Health Service highest-risk conditions criteria for early COVID-19 treatment, and had received outpatient treatment with sotrovimab, nirmatrelvir/ritonavir or molnupiravir, or no early COVID-19 treatment. Index date was defined as the earliest of either COVID-19-positive diagnosis or early COVID-19 treatment during the study period. Baseline patient characteristics and acute clinical outcomes in the 28 days following the index date were reported. To protect patient confidentiality, values of ≤5 were suppressed. Results A total of 2548 patients were included (492: sotrovimab, 276: nirmatrelvir/ritonavir, 71: molnupiravir, and 1709 eligible highest-risk untreated). Patients aged ≥75 years accounted for 6.9% (n=34/492) of the sotrovimab-treated group, 21.0% (n=58/276) of those treated with nirmatrelvir/ritonavir, 16.9% (n=12/71) of those treated with molnupiravir and 13.2% (n=225/1709) of untreated patients. Advanced renal disease was reported for 6.7% (n=33/492) of sotrovimab-treated and 4.7% (n=81/1709) of untreated patients, and five or fewer patients in the nirmatrelvir/ritonavir and molnupiravir cohorts. A high proportion of treated patients did not have a highest-risk condition reported in the database (71.7% for sotrovimab [n=353/492], 85.1% for nirmatrelvir/ritonavir [n=235/276], 85.9% for molnupiravir [n=61/71]). Five or fewer patients in each treated cohort experienced COVID-19-related hospitalisations during the 28-day acute period. For untreated patients, the percentage of COVID-19-related hospitalisations was 3.0% (n=48/1622). All-cause hospitalisations were experienced by 5.3% (n=25/476) of sotrovimab-treated patients, 6.9% (n=12/175) of nirmatrelvir/ritonavir-treated patients and 13.3% (n=216/1622) of untreated patients. Five or fewer patients in the molnupiravir cohort experienced all-cause hospitalisation. There were no deaths within 28 days of index for patients in the treated cohorts. Mortality was 4.3% (n=70/1622) in untreated patients (18.6% [n=13/70] had COVID-19 as the primary cause). In our analyses of outcomes for sotrovimab-treated and untreated patients during BA.1, BA.2 and BA.5 predominance, COVID-19-related hospitalisation rates were consistent, with n≤5 for sotrovimab-treated patients in each period. Conclusions Our findings indicate that sotrovimab was often used amongst patients who were aged <75 years old and had advanced renal disease. Among patients who received early COVID-19 treatment, proportions of all-cause hospitalisation and death within 28 days of treatment were low." @default.
• W4380355199 created "2023-06-13" @default.
• W4380355199 creator A5006273882 @default.
• W4380355199 creator A5016247746 @default.
• W4380355199 creator A5019238422 @default.
• W4380355199 creator A5025495401 @default.
• W4380355199 creator A5026215303 @default.
• W4380355199 creator A5031094293 @default.
• W4380355199 creator A5032942541 @default.
• W4380355199 creator A5042182538 @default.
• W4380355199 creator A5082811546 @default.
• W4380355199 date "2023-06-12" @default.
• W4380355199 modified "2023-10-18" @default.
• W4380355199 title "Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in Scotland" @default.
• W4380355199 cites W2159515958 @default.
• W4380355199 cites W2785308733 @default.
• W4380355199 cites W3025744748 @default.
• W4380355199 cites W3135758766 @default.
• W4380355199 cites W3194089520 @default.
• W4380355199 cites W4200051875 @default.
• W4380355199 cites W4211134995 @default.
• W4380355199 cites W4220848096 @default.
• W4380355199 cites W4226236384 @default.
• W4380355199 cites W4293063227 @default.
• W4380355199 cites W4295152060 @default.
• W4380355199 cites W4307523553 @default.
• W4380355199 cites W4309515692 @default.
• W4380355199 cites W4310368283 @default.
• W4380355199 cites W4311438499 @default.
• W4380355199 cites W4312193649 @default.
• W4380355199 cites W4317721984 @default.
• W4380355199 cites W4319937261 @default.
• W4380355199 cites W4376636591 @default.
• W4380355199 doi "https://doi.org/10.1101/2023.06.09.23291195" @default.
• W4380355199 hasPublicationYear "2023" @default.
• W4380355199 type Work @default.
• W4380355199 citedByCount "0" @default.
• W4380355199 crossrefType "posted-content" @default.
• W4380355199 hasAuthorship W4380355199A5006273882 @default.
• W4380355199 hasAuthorship W4380355199A5016247746 @default.
• W4380355199 hasAuthorship W4380355199A5019238422 @default.
• W4380355199 hasAuthorship W4380355199A5025495401 @default.
• W4380355199 hasAuthorship W4380355199A5026215303 @default.
• W4380355199 hasAuthorship W4380355199A5031094293 @default.
• W4380355199 hasAuthorship W4380355199A5032942541 @default.
• W4380355199 hasAuthorship W4380355199A5042182538 @default.
• W4380355199 hasAuthorship W4380355199A5082811546 @default.
• W4380355199 hasConcept C126322002 @default.
• W4380355199 hasConcept C142462285 @default.
• W4380355199 hasConcept C167135981 @default.
• W4380355199 hasConcept C187212893 @default.
• W4380355199 hasConcept C203014093 @default.
• W4380355199 hasConcept C2779134260 @default.
• W4380355199 hasConcept C2779298103 @default.
• W4380355199 hasConcept C2993143319 @default.
• W4380355199 hasConcept C3008058167 @default.
• W4380355199 hasConcept C3013748606 @default.
• W4380355199 hasConcept C524204448 @default.
• W4380355199 hasConcept C71924100 @default.
• W4380355199 hasConceptScore W4380355199C126322002 @default.
• W4380355199 hasConceptScore W4380355199C142462285 @default.
• W4380355199 hasConceptScore W4380355199C167135981 @default.
• W4380355199 hasConceptScore W4380355199C187212893 @default.
• W4380355199 hasConceptScore W4380355199C203014093 @default.
• W4380355199 hasConceptScore W4380355199C2779134260 @default.
• W4380355199 hasConceptScore W4380355199C2779298103 @default.
• W4380355199 hasConceptScore W4380355199C2993143319 @default.
• W4380355199 hasConceptScore W4380355199C3008058167 @default.
• W4380355199 hasConceptScore W4380355199C3013748606 @default.
• W4380355199 hasConceptScore W4380355199C524204448 @default.
• W4380355199 hasConceptScore W4380355199C71924100 @default.
• W4380355199 hasLocation W43803551991 @default.
• W4380355199 hasOpenAccess W4380355199 @default.
• W4380355199 hasPrimaryLocation W43803551991 @default.
• W4380355199 hasRelatedWork W2082482010 @default.
• W4380355199 hasRelatedWork W2105151527 @default.
• W4380355199 hasRelatedWork W2324013405 @default.
• W4380355199 hasRelatedWork W2765379856 @default.
• W4380355199 hasRelatedWork W3013145321 @default.
• W4380355199 hasRelatedWork W3032346208 @default.
• W4380355199 hasRelatedWork W3208090289 @default.
• W4380355199 hasRelatedWork W3210359220 @default.
• W4380355199 hasRelatedWork W4255376461 @default.
• W4380355199 hasRelatedWork W4367672288 @default.
• W4380355199 isParatext "false" @default.
• W4380355199 isRetracted "false" @default.
• W4380355199 workType "article" @default.